Updated on 7 September 2012
1. As per the 10th annual BioSpectrum-ABLE Biotech Industry Survey for India this year, "amidst uncertain economic conditions, the biotech industry has performed creditably to cross the $4 billion (Rs 20,000 crore) revenue mark for the first time ever. Last year's 18.5 percent growth has been built on the back of 19, 21, 17, 18, 20 percent growth rates, recorded in the previous five years respectively. It is clear that the industry growth will hover around 20 percent in the near future... Many other industry segments will be happy to have such a steady growth rate. This translates to a compounded annual growth rate (CAGR) of 14.75 percent in the last four years, and a CAGR of 24.18 percent between 2002 and 2012."
2. Other reports have stated that an opportunity worth $70 billion in similar biologics beckons India's biotech industry as we approach the "patent cliff" years of 2015-16.
3. Again, India's pharmaceutical industry has witnessed a robust growth from $11.4 billion in 2010, to $13 billion in 2011, to $17.4 billion in 2012, with a scorching pace of growth of 15 percent. The industry ranks third in terms of volume, globally. Projects worth more than $1.2 billion are currently under implementation at various stages, suggesting massive investments by Indian pharmaceutical companies.
4. Also, it is important to note that healthcare industry has grown from $71.8 billion in 2011 to $77.3 billion in 2012 at a growth of 7.6 percent (11 percent in Rupee terms).
5. The medical devices market has grown from $3 billion in 2011 to $3.2 billion in 2012, growth of eight percent (12.2 percent in Rupee terms)